PCAT6

Summary

PCAT6 (prostate cancer associated transcript 6, HGNC:43714) is a long non-coding RNA gene on chromosome 1q32.1.

At a glance

• Gene type: non-coding (lncRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:43714
Approved symbol	PCAT6
Name	prostate cancer associated transcript 6
Location	1q32.1
Locus type	RNA, long non-coding
Status	Approved
Aliases	ncRNA-a2, PCAN-R1, KDM5BAS1, onco-lncRNA-96
Ensembl gene	ENSG00000228288
Ensembl biotype	lncRNA
Entrez	100506696
RNAcentral	URS0002A14723 — lncRNA, 755 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 13 — 13 lncRNA

ENST00000330493, ENST00000417262, ENST00000425295, ENST00000553157, ENST00000660963, ENST00000686658, ENST00000728152, ENST00000728153, ENST00000728154, ENST00000728155, ENST00000728206, ENST00000728207, ENST00000728208

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000330493 — 3 exons

Exon	Start	End
ENSE00001300115	202823257	202823906
ENSE00001326127	202820266	202820385
ENSE00001444007	202825186	202827225

Expression profiles

Bgee: expression breadth ubiquitous, 190 present calls, max score 99.20.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 8.7451 / max 156.9776, expressed in 1564 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
7823	7.0448	1531
7824	1.4844	797
201878	0.1219	44
7822	0.0709	21
7821	0.0230	6

Top tissues by expression

243 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sperm	CL:0000019	99.20	gold quality
left testis	UBERON:0004533	96.43	gold quality
right testis	UBERON:0004534	96.42	gold quality
testis	UBERON:0000473	93.80	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	90.35	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	86.72	gold quality
skin of leg	UBERON:0001511	84.04	gold quality
skin of abdomen	UBERON:0001416	83.93	gold quality
lower esophagus mucosa	UBERON:0035834	83.41	gold quality
corpus epididymis	UBERON:0004359	82.88	gold quality
zone of skin	UBERON:0000014	82.31	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	80.64	gold quality
adenohypophysis	UBERON:0002196	80.30	gold quality
esophagus squamous epithelium	UBERON:0006920	79.62	gold quality
pituitary gland	UBERON:0000007	79.44	gold quality
esophagus mucosa	UBERON:0002469	79.34	gold quality
stromal cell of endometrium	CL:0002255	77.68	gold quality
adult organism	UBERON:0007023	76.89	gold quality
bone marrow cell	CL:0002092	76.45	gold quality
cortical plate	UBERON:0005343	75.58	gold quality
minor salivary gland	UBERON:0001830	75.40	gold quality
right adrenal gland cortex	UBERON:0035827	74.65	gold quality
left adrenal gland cortex	UBERON:0035825	74.61	gold quality
anterior cingulate cortex	UBERON:0009835	74.54	gold quality
ectocervix	UBERON:0012249	74.51	gold quality
mouth mucosa	UBERON:0003729	74.39	gold quality
amniotic fluid	UBERON:0000173	74.33	silver quality
right frontal lobe	UBERON:0002810	74.09	gold quality
left adrenal gland	UBERON:0001234	74.02	gold quality
esophagus	UBERON:0001043	73.97	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.22

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 22)

• PCAT6 is a novel potential oncogenic lncRNA in lung cancer. Combined with the results that high PCAT6 expression positively correlated with metastasis and showed poor overall survival in lung cancer patients, our studies suggest that PCAT6 may be a potential molecular therapeutic target or a prognostic marker for patients with lung cancer. (PMID:27458097)
• mechanistic investigation demonstrated that the oncogenic activity of PCAT6 is partially attributable to its repression of LATS2 via association with the epigenetic repressor EZH2 (Enhancer of zeste homolog 2). (PMID:30314898)
• Our data highlighted that PCAT6 acts as a key activator of ARC expression by forming a complex with EZH2, inhibiting cell apoptosis and contributing to colon cancer progression. These findings elucidated that PCAT6 may be a novel prognostic predictor and therapeutic target of colon cancer (PMID:30569799)
• Long noncoding RNA PCAT6 regulates cell growth and metastasis via Wnt/beta-catenin pathway and is a prognosis marker in cervical cancer. (PMID:30915737)
• we demonstrate that the abnormal PCAT6 overexpression inhibits miR-204 expression in CRC, thereby promoting HMGA2/PI3K signaling activity, ultimately enhancing the chemoresistance of CRC cells to 5-FU; PCAT6 represents a promising target for dealing with CRC chemoresistance. (PMID:30938104)
• LncRNA PCAT6 promotes occurrence and development of ovarian cancer by inhibiting PTEN. (PMID:31646553)
• PCAT6, acting as a competitive endogenous RNA, upregulated expression of TGFBR1 and TGFBR2 to activate TGF-beta pathway via sponging miR-185-5p. (PMID:31676070)
• Silencing of long non-coding RNA PCAT6 restrains gastric cancer cell proliferation and epithelial-mesenchymal transition by targeting microRNA-15a. (PMID:32039820)
• LncRNA PCAT6 predicts poor prognosis in hepatocellular carcinoma and promotes proliferation through the regulation of cell cycle arrest and apoptosis. (PMID:32064636)
• PCAT6 mediates cellular biological functions in gastrointestinal stromal tumor via upregulation of PRDX5 and activation of Wnt pathway. (PMID:32339330)
• M2 macrophage-induced lncRNA PCAT6 facilitates tumorigenesis and angiogenesis of triple-negative breast cancer through modulation of VEGFR2. (PMID:32908134)
• LncRNA PCAT6 Regulated by YY1 Accelerates the Progression of Glioblastoma via miR-513/IGF2BP1. (PMID:32990800)
• LncRNA PCAT6 aggravates the progression of bladder cancer cells by targeting miR-513a-5p. (PMID:33090394)
• Long noncoding RNA PCAT6 promotes the development of osteosarcoma by increasing MDM2 expression. (PMID:33125146)
• LncRNA PCAT6: A potential biomarker for diagnosis and prognosis of bladder cancer. (PMID:33142195)
• Promising role of long non-coding RNA PCAT6 in malignancies. (PMID:33761616)
• m(6) A modification of lncRNA PCAT6 promotes bone metastasis in prostate cancer through IGF2BP2-mediated IGF1R mRNA stabilization. (PMID:34185427)
• Long non-coding RNA prostate cancer-associated transcript 6 inhibited gefitinib sensitivity of non-small cell lung cancer by serving as a competing endogenous RNA of miR-326 to up-regulate interferon-alpha receptor 2. (PMID:35081872)
• Knockdown of lncRNA PCAT6 suppresses the growth of non-small cell lung cancer cells by inhibiting macrophages M2 polarization via miR-326/KLF1 axis. (PMID:35609331)
• LncRNA PCAT6 promotes proliferation, migration, invasion, and epithelial-mesenchymal transition of lung adenocarcinoma cell by targeting miR-545-3p. (PMID:36787056)
• Pan-cancer analysis of PCAT6 and its effect on oesophageal squamous cell carcinoma cell proliferation and migration. (PMID:36949349)
• Prostate cancer-associated transcript 6 (PCAT6) promotes epithelial-mesenchymal transition and stemness and worsens prognosis in patients with colorectal cancer. (PMID:38606479)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.